Drug Profile
Nitric oxide inhalation - Novoteris
Alternative Names: ThiolanoxLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Novoteris
- Developer Mallinckrodt Inc.; Nitric Solutions; Novoteris; University of British Columbia; University of Toronto
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections; Cystic fibrosis; Mycobacterial infections; Nontuberculous mycobacterium infections
- No development reported Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 16 Jul 2021 Mallinckrodt in collaboration with Mallinckrodt terminates a phase II NONTM trial in Non-tuberculous mycobacterium infection and COVID-2019 infections, in Canada, due to low no. of COVID-2019 patients and funding(NCT03331445)
- 09 Mar 2021 Phase-II development is ongoing in Mycobacterium infection (Treatment-experienced) in Canada (Inhalation) (NCT03473314)
- 01 Apr 2020 Therapeutic Products Directorate of Health Canada approves IND application for Nitric oxide inhalation (Thiolanox) in COVID-2019 infections